Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuneering Corp Director's Dealing 2021

Aug 4, 2021

32973_dirs_2021-08-04_30b84f2a-e4ba-466c-89df-7732de4352a8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2021-08-03

Reporting Person: CARPENTER ROBERT J (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-08-03 Class A Common Stock C 217173 Acquired 823839 Direct
2021-08-03 Class A Common Stock P 325000 $15.00 Acquired 1148839 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-08-03 Series A Preferred Stock $ C 94585 Disposed Class A Common Stock (94585) Direct
2021-08-03 Series B Preferred Stock $ C 122588 Disposed Class A Common Stock (122588) Direct

Footnotes

F1: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.